Pharmacology of fenofibrate
- PMID: 3318449
- DOI: 10.1016/0002-9343(87)90867-9
Pharmacology of fenofibrate
Abstract
This discussion outlines the major aspects of the human pharmacology of fenofibrate, a hypolipidemic agent. In view of its short half-life, efficient absorption, and elimination, fenofibrate would not appear to accumulate in either plasma or tissues. It is extensively absorbed only in the presence of food and is transported through the bloodstream by albumin. Fenofibrate is taken up by both the liver and kidney. Except for a small percentage (about 5 percent) reduced at the ketone moiety before conjugation, most drug is excreted as a conjugate in the urine. Less than 20 percent is excreted through the bile. In normal persons, at steady state with usual doses of 100 mg three times daily, the plasma half-life approximates 30 hours. Because fenofibrate is not dialyzable, it has a markedly prolonged half life in patients with renal failure and should not be used.
Similar articles
-
[Pharmacokinetics of fenofibrate in man (author's transl)].Nouv Presse Med. 1980 Dec 22;9(49):3725-7. Nouv Presse Med. 1980. PMID: 7208337 French.
-
Clinical pharmacokinetics of prazosin.Clin Pharmacokinet. 1980 Jul-Aug;5(4):365-76. doi: 10.2165/00003088-198005040-00004. Clin Pharmacokinet. 1980. PMID: 6994981 Review.
-
Metabolism of flecainide.Am J Cardiol. 1984 Feb 27;53(5):41B-51B. doi: 10.1016/0002-9149(84)90501-0. Am J Cardiol. 1984. PMID: 6364769 Review.
-
The biochemical pharmacology of fenofibrate.Cardiology. 1989;76 Suppl 1:33-41; discussion 41-4. doi: 10.1159/000174545. Cardiology. 1989. PMID: 2713875
-
Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure.Nephron. 1982;31(1):51-4. doi: 10.1159/000182614. Nephron. 1982. PMID: 7110477
Cited by
-
Fenofibrate and metabolic syndrome.Endocr Metab Immune Disord Drug Targets. 2010 Jun;10(2):138-48. doi: 10.2174/187153010791213047. Endocr Metab Immune Disord Drug Targets. 2010. PMID: 20406163 Free PMC article. Review.
-
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.Cardiovasc Drugs Ther. 2012 Jun;26(3):245-55. doi: 10.1007/s10557-012-6394-0. Cardiovasc Drugs Ther. 2012. PMID: 22592524 Free PMC article. Review.
-
Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis.J Clin Lipidol. 2015 May-Jun;9(3):326-33. doi: 10.1016/j.jacl.2015.02.004. Epub 2015 Feb 21. J Clin Lipidol. 2015. PMID: 26073390 Free PMC article. Clinical Trial.
-
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.Vasc Health Risk Manag. 2010 Aug 9;6:525-39. doi: 10.2147/vhrm.s5593. Vasc Health Risk Manag. 2010. PMID: 20730069 Free PMC article. Review.
-
Distribution of fenofibric acid in lipoprotein fractions of patients.Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):287-94. doi: 10.1007/BF03189353. Eur J Drug Metab Pharmacokinet. 1998. PMID: 9725495 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources